Amivas Ireland Ltd is a wholly owned subsidiary of Amivas Inc. focused on the development, manufacturing, and commercialization of therapeutics for the treatment of infectious diseases for the European and UK markets.
Amivas Inc was formed in response to the urgent need for a US -based firm to assume responsibility for the manufacture and distribution of Artesunate for Injection, for severe malaria after quinidine gluconate was discontinued by the manufacturer within the USA.
For more information about Amivas Ireland Ltd and Artesunate for Injection, please see our most recent press release.
Read about a new severe malaria product and how to order. This innovative malaria treatment is our first registered medication for slow bolus intravenous delivery. Artesunate for Injection is administered during hospitalization. It is suitable for the treatment of patients with severe malaria. It is recommended that Artesunate Amivas should be used to treat patients with severe malaria only after consultation with a physician with appropriate experience in the management of malaria.